Evidence map›Paper›PMID 36730465›Full record

ArticlePLoS pathogens2023

An NlpC/P60 protein catalyzes a key step in peptidoglycan recycling at the intersection of energy recovery, cell division and immune evasion in the intracellular pathogen Chlamydia trachomatis.

Jula Reuter, Christian Otten, Nicolas Jacquier, Junghoon Lee, Dominique Mengin-Lecreulx, Iris Löckener, Robert Kluj, Christoph Mayer, Federico Corona, Julia Dannenberg and 7 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Infection and immunity · 2026
    Article
  3. Article
  4. Article
  5. mSphere · 2024
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 5 countries.

Jula ReuterInstitute for Pharmaceutical Microbiology, University Hospital Bonn, University of Bonn, Bonn, Germany.
Christian OttenInstitute for Pharmaceutical Microbiology, University Hospital Bonn, University of Bonn, Bonn, Germany.
Nicolas JacquierInstitute of Microbiology, University Hospital Center and University of Lausanne, Lausanne, Switzerland.
Junghoon LeeDepartment of Pathology and Microbiology, College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.
Dominique Mengin-LecreulxUniversité Paris-Saclay, CEA, CNRS, Institute for Integrative Biology of the Cell (I2BC), Gif-sur-Yvette, France.
Iris LöckenerInstitute for Pharmaceutical Microbiology, University Hospital Bonn, University of Bonn, Bonn, Germany.
Robert KlujInterfaculty Institute of Microbiology and Infection Medicine, Organismic Interactions/Glycobiology, Eberhard Karls Universität Tübingen, Tübingen, Germany.
Christoph MayerInterfaculty Institute of Microbiology and Infection Medicine, Organismic Interactions/Glycobiology, Eberhard Karls Universität Tübingen, Tübingen, Germany.
Federico CoronaCentre for Bacterial Cell Biology, Biosciences Institute, Newcastle University, Newcastle Upon Tyne, United Kingdom.
Julia DannenbergInstitute for Pharmaceutical Microbiology, University Hospital Bonn, University of Bonn, Bonn, Germany.
Sébastien AebyInstitute of Microbiology, University Hospital Center and University of Lausanne, Lausanne, Switzerland.
Henrike BühlInstitute for Pharmaceutical Microbiology, University Hospital Bonn, University of Bonn, Bonn, Germany.
Gilbert GreubInstitute of Microbiology, University Hospital Center and University of Lausanne, Lausanne, Switzerland.
Waldemar VollmerCentre for Bacterial Cell Biology, Biosciences Institute, Newcastle University, Newcastle Upon Tyne, United Kingdom.
Scot P OuelletteDepartment of Pathology and Microbiology, College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.
Tanja SchneiderInstitute for Pharmaceutical Microbiology, University Hospital Bonn, University of Bonn, Bonn, Germany.
Beate HenrichfreiseInstitute for Pharmaceutical Microbiology, University Hospital Bonn, University of Bonn, Bonn, Germany.
University of Bonn · DEUniversity of Lausanne · CHNewcastle University · GBUniversity of Nebraska Medical Center · USUniversity of Tübingen · DECentre National de la Recherche Scientifique · FR

Funding

Polarized Chlamydial Cell Division in the Absence of FtsZR35GM124798 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI OUELLETTE, SCOT P · 2017 to 2021
$1.8M
NIGMS NIH HHS R35 GM124798
6 · The paper itself

Abstract

The obligate intracellular Chlamydiaceae do not need to resist osmotic challenges and thus lost their cell wall in the course of evolution. Nevertheless, these pathogens maintain a rudimentary peptidoglycan machinery for cell division. They build a transient peptidoglycan ring, which is remodeled during the process of cell division and degraded afterwards. Uncontrolled degradation of peptidoglycan poses risks to the chlamydial cell, as essential building blocks might get lost or trigger host immune response upon release into the host cell. Here, we provide evidence that a primordial enzyme class prevents energy intensive de novo synthesis and uncontrolled release of immunogenic peptidoglycan subunits in Chlamydia trachomatis. Our data indicate that the homolog of a Bacillus NlpC/P60 protein is widely conserved among Chlamydiales. We show that the enzyme is tailored to hydrolyze peptidoglycan-derived peptides, does not interfere with peptidoglycan precursor biosynthesis, and is targeted by cysteine protease inhibitors in vitro and in cell culture. The peptidase plays a key role in the underexplored process of chlamydial peptidoglycan recycling. Our study suggests that chlamydiae orchestrate a closed-loop system of peptidoglycan ring biosynthesis, remodeling, and recycling to support cell division and maintain long-term residence inside the host. Operating at the intersection of energy recovery, cell division and immune evasion, the peptidoglycan recycling NlpC/P60 peptidase could be a promising target for the development of drugs that combine features of classical antibiotics and anti-virulence drugs.

Indexed as

Chlamydia trachomatisPeptidoglycanBacterial ProteinsCell DivisionCell WallImmune EvasionPeptide HydrolasesBacterial ProteinsPeptide HydrolasesPeptidoglycan

Identifiers

PMID36730465
PMCPMC9928106
OpenAlexW4318955917

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.